LE 300

Biological Activity

Technical Data

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.

Background References

1. Treatment with the antipsychotic agent, risperidone, reduces disease severity in experimental autoimmune encephalomyelitis.
   O'Sullivan D, Green L, Stone S, Zareie P, Kharkrang M, Fong D, Connor B, La Flamme A
   PLoS ONE, 2014;9(8):e104430.
2. DA/serotonin receptor ligands: Part IV [1]: Synthesis and pharmacology of novel 3-benzazecines and 3-benzazonines as potential 5-HT_2A and DA receptor ligands.
   El-Subbagh et al.
   Arch.Pharm. (Weinheim)., 2002;9:443
3. Pharmacological characterization of the benz[d]indolo[2,3-g]azecine LE300, a novel type of a nanomolar DA receptor antagonist.
   Kassack et al.
   Naunyn Schmiedebergs Arch.Pharmacol., 2002;366:543
4. 7-Methyl-6,7,8,9,14,15-hexahydro-5H-benz[d]indolo[2,3-g]azecine: a new heterocyclic system and a new lead compound for DA receptor antagonists.
   Witt et al.
   J.Med.Chem., 2000;43:2079

Product Datasheets